Evommune (EVMN) director reports preferred conversion and 1.56M share buy

Rhea-AI Filing Summary

Evommune, Inc. insider LSP 7 Management B.V., as director of LSP 7 Cooperatief U.A., reported multiple equity transactions dated 11/07/2025. All outstanding shares of Series A, Series B, and Series C preferred stock automatically converted into common stock immediately before Evommune’s initial public offering, for no additional consideration, at fixed ratios for each series. Following these conversions, the reporting person bought an additional 1,562,500 shares of common stock at $16 per share. After the reported transactions, LSP 7 Cooperatief U.A. directly held 4,929,633 shares of Evommune common stock.

Insider Trade Summary

Net Buyer: 1,562,500 shares ($25,000,000)

Net Buy 5 txns

Insider LSP 7 Cooperative UA

Role 10% Owner

Bought 1,562,500 shs ($25.00M)

Type	Security	Shares	Price	Value
Conversion	Series A Preferred Stock	15,493,466	$0.00	--
Conversion	Series B Preferred Stock	5,090,000	$0.00	--
Conversion	Series C Preferred Stock	6,585,011	$0.00	--
Conversion	Common Stock	3,367,133	$0.00	--
Purchase	Common Stock	1,562,500	$16.00	$25.00M

Holdings After Transaction: Series A Preferred Stock — 0 shares (Direct); Series B Preferred Stock — 0 shares (Direct); Series C Preferred Stock — 0 shares (Direct); Common Stock — 3,367,133 shares (Direct)

Footnotes (1)

1. Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date. Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date. Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date. The securities are directly held by LSP 7 Cooperatief U.A., of which, LSP 7 Management B.V. is the sole director. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LSP 7 Cooperative UA

(Last) (First) (Middle)

JOHANNES VERMEERPLEIN 9

(Street)

AMSTERDAM P7 1071 DV

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/07/2025		C		3,367,133	A	(1)(2)(3)	3,367,133	D(4)
Common Stock	11/07/2025		P		1,562,500	A	$16	4,929,633	D(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Preferred Stock	(1)	11/07/2025		C			15,493,466	(1)	(1)	Common Stock	1,947,477	(1)	0	D(4)
Series B Preferred Stock	(2)	11/07/2025		C			5,090,000	(2)	(2)	Common Stock	646,587	(2)	0	D(4)
Series C Preferred Stock	(3)	11/07/2025		C			6,585,011	(3)	(3)	Common Stock	773,069	(3)	0	D(4)

Explanation of Responses:

1. Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date.

2. Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

3. Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

4. The securities are directly held by LSP 7 Cooperatief U.A., of which, LSP 7 Management B.V. is the sole director. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe.

	By LSP 7 Management B.V., its director, By /s/ Martijn Kleijwegt, Managing Director	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Evommune (EVMN) disclose in this Form 4?

The filing reports automatic conversion of Series A, B and C preferred stock into common stock and a purchase of 1,562,500 common shares at $16 per share on 11/07/2025.

How many Evommune (EVMN) common shares does the reporting person hold after these transactions?

After the reported transactions, LSP 7 Cooperatief U.A., related to the reporting person, directly held 4,929,633 shares of Evommune common stock.

What happened to Evommune’s preferred stock in this insider filing?

Each share of Series A, Series B, and Series C Preferred Stock automatically converted into common stock immediately before Evommune’s IPO, on a stated share-for-share basis, for no additional consideration and with no expiration date.

Who is the reporting person in this Evommune (EVMN) Form 4?

The securities are directly held by LSP 7 Cooperatief U.A., whose sole director is LSP 7 Management B.V.; its managing directors are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe.

What price was paid for the newly purchased Evommune (EVMN) common shares?

The Form 4 shows a purchase transaction code "P" for 1,562,500 Evommune common shares at a price of $16 per share.

What is the relationship of the reporting person to Evommune (EVMN)?

The Form 4 identifies the reporting person’s relationship to Evommune as a Director, and the form is filed for one reporting person.